Morepen Laboratories Share Price Rises 5%, Hits Upper Circuit As Profit More Than Doubles

Mumbai, October 27: Morepen Laboratories share price rose 5% to hit upper circuit as net profit more than doubled for the second quarter of FY2026-27, up 117% to Rs 89 crore. Revenue increased 81% to ₹755 crore, while EBITDA rose 273% to ₹132 crore compared with the corresponding quarter of the previous financial year. The company attributed its performance to business growth across key segments, including APIs, CDMO services and medical devices. Its results also highlighted improving operating efficiency and ongoing investments to expand manufacturing capacity and strengthen its pharmaceutical business.

Morepen Laboratories Sees Strong H1 Growth as CDMO Business Gains Momentum

Morepen Laboratories’ quarterly performance reflected growth across its core business operations. The company’s EBITDA margin improved to 17.5%, compared with 8.1% in the year-ago quarter, indicating an improvement in operating profitability. For the first half of FY2026-27, revenue increased 57% year-on-year to ₹1,330 crore, while EBITDA rose 243% to ₹220 crore. The EBITDA margin reached 16.5%, compared with 6.9% in the corresponding period last year. The CDMO business continued to gain importance, contributing ₹253 crore in Q2 revenue, compared with ₹58 crore in the first quarter of FY2026-27. The segment accounted for approximately 32% of combined API and CDMO revenue during the quarter. The company also reported progress in its API portfolio and medical devices business. Its expansion plans include increasing manufacturing capacity and strengthening its product pipeline to support future demand.

About Morepen Laboratories Limited

Morepen Laboratories Limited is an Indian pharmaceutical and healthcare company engaged in the manufacturing and marketing of active pharmaceutical ingredients, pharmaceutical formulations and medical devices. The company has an established presence in API manufacturing and is expanding its CDMO business by offering contract manufacturing and development services. Its medical devices portfolio includes products used for blood glucose and blood pressure monitoring. Morepen Laboratories is also investing in manufacturing capacity, regulatory capabilities and product development to support its growth strategy across domestic and international markets.

Conclusion

Morepen Laboratories reported strong Q2 FY2026-27 results, with revenue rising 81% year-on-year to ₹755 crore and EBITDA increasing 273% to ₹132 crore. Growth in APIs, CDMO operations and medical devices contributed to the company’s performance, while improved EBITDA margins reflected stronger operating profitability. Investors may monitor future revenue growth, margin sustainability, capacity utilisation and the contribution of the CDMO business to assess the company’s outlook.

Source: 

• https://www.nseindia.com/get-quote/equity/MOREPENLAB/Morepen-Laboratories-Limited